Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | DRD4 | P21917 | 4/20 | 0.32 |
| ▸ | DRD3 | P35462 | 4/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456943 | 0.78 | HTT (0.42) | HTTNPC1RAB9AIKBKBDRD2 | |
| SCHEMBL1457384 | 0.77 | TOP1 (0.41) | HTTNPC1RAB9AIKBKBDRD2 | |
| SCHEMBL1456957 | 0.76 | TLR7 (0.49) | HTTNPC1RAB9AIKBKBDRD2 | |
| SCHEMBL3353644 | 0.69 | TLR7 (0.49) | HTTNPC1RAB9A | |
| SCHEMBL1457397 | 0.67 | HTT (0.45) | HTTNPC1RAB9ADRD2DRD4 | |
| SCHEMBL1457009 | 0.66 | HTT (0.42) | HTTNPC1RAB9ADRD2DRD4 | |
| SCHEMBL1456665 | 0.63 | NPC1 (0.36) | NPC1RAB9ADRD2DRD4DRD3 | |
| SCHEMBL1456641 | 0.63 | HTT (0.41) | HTTNPC1RAB9ADRD2DRD4 | |
| SCHEMBL1456858 | 0.63 | TLR7 (0.41) | NPC1RAB9ADRD2DRD4DRD3 | |
| SCHEMBL1456911 | 0.62 | TOP1 (0.41) | NPC1RAB9ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | IFNG, IL4, IL2 | HTT 4596/4885NPC1 2667/4885RAB9A 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.